IP Library › Granted Patent US 12,286,402
Granted Patent B2
US 12,286,402 · App. 17/839,234 · Granted Apr 29, 2025

Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Inventors: Nigel Ramsden (Cambridge, GB); David John Fox (Coventry, GB); James Andrew Huntington (Cheshire, GB); James Michael Tomlinson (Babraham, GB)
Assignee: CENTESSA PHARMACEUTICALS (UK) LIMITED
C07D213/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,286,402
App. No.
17/839,234
Filed
Jun 13, 2022
Granted
Apr 29, 2025
Kind
B2
Art Unit
1625
USPC
514/351
Abstract

The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of α 1 -antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as α 1 -antitrypsin deficiency (A1AD or AATD).

Claims (37)

1. A compound represented by the structure:

or a pharmaceutically acceptable salt of any one thereof.

2. The compound of claim 1 , wherein the compound is in a crystalline form.

3. A pharmaceutical composition comprising a compound represented by the structure:

or a pharmaceutically acceptable salt of any one thereof, and a pharmaceutically acceptable carrier.

4. A method of inducing Z A1AT secretion in a subject in need thereof, comprising administering to the subject a compound represented by the structure:

or a pharmaceutically acceptable salt of any one thereof.

5. The compound of claim 1 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

10. The pharmaceutical composition of claim 3 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

11. The pharmaceutical composition of claim 3 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

12. The pharmaceutical composition of claim 3 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical composition of claim 3 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

14. The pharmaceutical composition of claim 3 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

15. The method of claim 4 , wherein the structure is represented by:

or a pharmaceutically acceptable salt thereof.

16. The method of claim 4 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

17. The method of claim 4 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

18. The method of claim 4 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

19. The method of claim 4 , wherein the compound is represented by:

or a pharmaceutically acceptable salt thereof.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 24, 2026
From: OXFORD FINANCE LLC
To: CENTESSA PHARMACEUTICALS (UK) LIMITED
Reel/Frame 075069/0879 →
SECURITY INTEREST Recorded Dec 31, 2024
From: CENTESSA PHARMACEUTICALS (UK) LIMITED
To: OXFORD FINANCE LLC
Reel/Frame 069708/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2023
From: Z FACTOR LIMITED
To: CENTESSA PHARMACEUTICALS (UK) LIMITED
Reel/Frame 065294/0323 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2022
From: RAMSDEN, NIGEL, DR.; FOX, DAVID JOHN, DR.; HUNTINGTON, JAMES ANDREW; TOMLINSON, JAMES MICHAEL, DR.
To: Z FACTOR LIMITED
Reel/Frame 061931/0462 →
Priority Claims (1)
GB 1918413 · Dec 13, 2019 · national
Continuity (2)
Continuation PCTGB2020053192 · Dec 11, 2020
Related Publication 20230129181A1 · Apr 27, 2023
References Cited (22)
US 8436013B2 · Liu et al. · 2013 [cited by applicant]
US 20200361939A1 · Bandarage et al. · 2020 [cited by applicant]
WO WO03068230A1 · 2003 [cited by applicant]
WO WO2005018557A2 · 2005 [cited by applicant]
WO WO2008143633A2 · 2008 [cited by applicant]
WO WO2011056222A1 · 2011 [cited by applicant]
WO WO2019243841A1 · 2019 [cited by applicant]
WO WO2020081257A1 · 2020 [cited by applicant]
WO WO2021116707A1 · 2021 [cited by applicant]
Berthelier et al. Discovery of an Inhibitor of Z-Alpha1 Antitrypsin Polymerization. PLoS One 10(5):e0126256 (May 11, 2015). [cited by applicant]
Bouchecareilh et al. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency. J Biol Chem 287(45):38265-38278 (2012). [cited by applicant]
Burrows et al. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. PN… [cited by applicant]
Certified GB1918413, Filed Dec. 13, 2019. [cited by applicant]
Chang et al. Small-molecule peptides inhibit Z alpha1-antitrypsin polymerization. J. Cell. Mol. Med. 13(8B):2304-2316 (2009). [cited by applicant]
Elliott et al. Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Science 9:1274-1281 (2000). [cited by applicant]
GB1918413 Search Report dated May 22, 2020. [cited by applicant]
Gould et al. Salt Selection for Basic Drugs. Int J. Pharm. 33:201-217 (1986). [cited by applicant]
Huntington. How and why the Z variant of α1-antitrypson polymerises, and what can be done about it. 7th International Symposium on Serpin Biology, Structure and Function (Apr. 1, 2014). [cited by applicant]
Knaupp et al. Kinetic instability of the serpin Z alpha1-antitrypsin promotes aggregation. J. Mol. Biol. 396:375-383 (2010). [cited by applicant]
Mallya et al. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem 50(22):5357-5363 (2007). [cited by applicant]
Parfrey et al. Targeting a surface cavity of alpha 1-antitrypsin to prevent conformational disease. J. Biol. Chem. 278(35):33060-33066 (2003). [cited by applicant]
PCT/GB2020/053192 International Search Report and Written Opinion dated Mar. 26, 2021. [cited by applicant]